Feedback Share Discussion Threads

[ged5] 21/5/2020 20:18

Thanks LR2

No problem Euclid5.

There was mention earlier today about a need for a placing. I repeat an earlier post.

How much income is being generated from TexRAD research The distribution is left to GE Healthcare as per previous agreement so there'll probably be some.

How much if anything is coming from Cadran?

How much is being generated from the licencing agreement for fluoroscopy upgrades in the US

How much more are we spending on salaries for new appointments?

Will we have a placing or sell TexRAD or even get a grant to develop and scale Bleepa?

Are Feedback in the top ten of companies in some sort of (prestigious?) list?

Could anyone please advise me of the answer to any of these questions?

[euclid5] 21/5/2020 19:32

Thanks for the info Ged5

Yump, re market looks at potential, but not when it runs into sveral years of being potential - untimatley they want to see real revenue - growth & pBleepa product can secure a revenue contract in the not too distant future

[lr2] 21/5/2020 18:18

Papworth takes advanced Bleepa technology from Feedback

[yump] 21/5/2020 16:54

Whenever the volume picks up, there's a load of selling. It could just be as simple as a ready supply of shares. If that wasn't there, there might be big blue days. All we know is it can't keep making whoever it is a load of profit for ever.

[sonie01] 21/5/2020 15:03

Accepted dc but the dilution was about 20%

[lr2] 21/5/2020 15:02

Why is the Papworth contract for 14 months this time? Usually 24.

Is it just an RNS mistype? Same price outlay but shorter term? Free Bleepa Covid-19 end date?

Any other theories guys?

[ducatiman] 21/5/2020 14:47

More shares sonie

[yump] 21/5/2020 13:16

‘The market’ quite often values based on potential, not revenue. Very difficult to say why or to identify the ‘favoured̵7; businesses.

[ged5] 21/5/2020 12:48

Euclid5, the figures for Cadran were given by the ex-chairman at about 5.02 in this interview. More than I stated earlier today.



If you look on the website you'll see Bleepa is free during this Coronavirus outbreak.

They are trying to get a foothold in the NHS.

[euclid5] 21/5/2020 12:34

what are the value in revenue terms of this Bleepa contract to Papworth Hospital - no figures on that as yet - market wants to see revenue figure to re rate this

[ged5] 21/5/2020 12:22

I don't really know what people want anymore, Digger.

Last month Bleepa was rolled out in the Pennine Acute Hospitals Trust and Bleepa was to be used in the Recovery Trial.

This month a contract was renewed and Bleepa was introduced to a second Trust.

Next month there's the Digital Leaders session. It isn't the usual session we're used to on AIM. It looks to me there are a few influential people on the Advisory Board and have a look at who's giving the quotes just underneath them.

Some may sell at a small profit and good look if it's a few trading shares but I don't think some realise what is going on here but it won't be overnight.

[digger2779] 21/5/2020 12:04

Great news but a disappointing effect on share price to say the least.

[ducatiman] 21/5/2020 10:17

If we don’t finish blue today I will get my coat!
Cadran renewed, Bleepa into a second trust area.

[davydoo] 21/5/2020 10:07

I love Bleepa, and its potential, but successful clinical trials are not remotely the same thing as shipping some extra software functionality

[ged5] 21/5/2020 09:33

DrTomOakley and Prof Rory Shaw discuss how Bleepa can facilitate immediate responses between clinicians, and why this is essential in the tackling the #COVID19 pandemic.



Selected clip from the recent Livestream chat

[yump] 21/5/2020 09:32

Some medical stocks go crazy if there’s any hint of successful trials, so one step at a time will do me !

Be nice to get something about other trusts at some point.

[davydoo] 21/5/2020 09:03

With no numbers, it reads to me like they threw Bleepa in for free.

Sure it might help sell more Cadran, but people already expect technology to keep improving.

[yump] 21/5/2020 08:58

Yes that pretty much confirms successful trials - quite a big step.

[ged5] 21/5/2020 08:28

The first bit of good news since last month allows a few with pent up frustrations to bail out! Keep those sells coming!

[ged5] 21/5/2020 08:18

There's one of our questions answered, Ducatiman.

So the delay for the contract renewal was the inclusion of Bleepa. Cadran was previously reported as £120k licence fee.

2seabass, there are 100 consultants listed at Papworth:-

[jbe81] 21/5/2020 08:17

Nice to see a bit of progress being made

[philjeans] 21/5/2020 08:01

Great news FDBK - two down; hundreds more to come.

[2seabass] 21/5/2020 07:43

I Believe approx 100 clinicians at p/worth. I like the fact they also deal with respiratory conditions ... perhaps useful for CV19 ? !!